洛铂用于结直肠癌术中腹腔灌洗化疗的近期疗效分析  

The short-term effect analysis of intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin for colorectal cancer

作　　者：苏昊 周海涛 王锡山 关旭 赵志勋 周志祥 刘骞 王鹏 王雪玮 包满都拉 张育荣 马运宾 周金涛 陈怀堽 刘明 史薪祥 梁建伟 裴炜 刘正 姜争 郑朝旭 Su Hao;Zhou Haitao;Wang Xishan;Guan Xu;Zhao Zhixun;Zhou Zhixiang;Liu Qian;Wang Peng;Wang Xuewei;Bao Mandula;Zhang Yurong;Ma Yunbing;Zhou Jintao;Chen Huaigang;Liu Ming;Shi Xinxiang;Liang Jianwei;Pei Wei;Liu Zheng;Jiang Zheng;Zhen Zhaoxu(Department of Colorectal Surgery,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100021,China;Department of Surgery,Beijing Third Ring Road Cancer Hospital,Beijing 100021,China)

机构地区：[1]国家癌症中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科,北京100021 [2]北京三环肿瘤医院外科,100021

出　　处：《中华结直肠疾病电子杂志》2018年第2期125-129,共5页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：国家自然科学基金面上项目(No.81572930);国家重点研发计划精准医学研究专项(No.2016YFC0905300);2017年度北京市东城区优秀人才培养专项;中国癌症基金会北京希望马拉松基金(No.LC2016B10);中国医学科学院医学与健康科技创新工程(协同创新团队项目)(No.2017-I2M-4-002)

摘　　要：目的探讨洛铂用于结直肠癌术中腹腔灌洗化疗的安全性和可行性。方法选取中国医学科学院肿瘤医院结直肠外科在2016年11月1日至2017年11月1日行结直肠癌根治术的患者160例,采用随机数余数分组法前瞻性随机分为洛铂灌洗化疗组(研究组)80例和无腹腔化疗组(对照组)80例,研究组术中行洛铂腹腔灌洗化疗,对照组不行腹腔化疗。分析两组术后肠道功能恢复、血液和肝肾功能毒性以及术后并发症等近期疗效的差异。结果研究组和对照组术后总并发症发生率相似,分别为11.2%和12.5%(χ2=0.060,P=0.807)。两组患者术后肠道功能恢复状况、白细胞和血小板水平以及术后出现肝肾功能异常、消化道反应患者数量之间差异也均无统计学意义(均P>0.05)。结论洛铂术中腹腔灌洗化疗并不增加结直肠癌患者毒副反应及术后并发症,具有良好的安全性和可行性。Objective To explore the safety and feasibility of intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin for colorectal cancer.Methods Between November 1st 2016 to November 1st 2017,160 colorectal cancer(CRC)patients who underwent radical surgery were divided into 2 groups randomly:the Lobaplatin group(80 patients),who received intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin and the control group(80 patients),who did not receive intraoperative intraperitoneal perfusion chemotherapy.Patients of the two groups were observed for the time of postoperative intestinal function recovery,hematotoxicity,hepatic-renal toxicity and postoperative complications.Results The overall incidence of postoperative complications in the Lobaplatin group was 11.2%,similar to 12.5%in the control group(χ2=0.060,P=0.807).There was no significant statistical difference between both groups on the time of exsufflation and defecation,the level of postoperative leukocyte and platelet,the number of patients with abnormal hepatic-renal function and gastrointestinal reaction(P>0.05).Conclusions Intraoperative intraperitoneal perfusion chemotherapy with Lobaplatin shows no negative effects on short-term recovery in CRC patients and it is safe and feasible.

关 键 词：结直肠肿瘤 手术 洛铂 腹腔化疗 术中化疗 

分 类 号：R735.34[医药卫生—肿瘤]